Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $10.3 million.

  • Relay Therapeutics' Change in Accured Expenses fell 144.36% to -$507,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 251.73%. This contributed to the annual value of $10.3 million for FY2024, which is 141.16% up from last year.
  • According to the latest figures from FY2024, Relay Therapeutics' Change in Accured Expenses is $10.3 million, which was up 141.16% from -$24.9 million recorded in FY2023.
  • Relay Therapeutics' 5-year Change in Accured Expenses high stood at $21.0 million for FY2021, and its period low was -$24.9 million during FY2023.
  • In the last 3 years, Relay Therapeutics' Change in Accured Expenses had a median value of $10.3 million in 2024 and averaged -$1.1 million.
  • In the last 5 years, Relay Therapeutics' Change in Accured Expenses spiked by 944.88% in 2021 and then tumbled by 320.99% in 2023.
  • Yearly analysis of 5 years shows Relay Therapeutics' Change in Accured Expenses stood at $2.0 million in 2020, then surged by 944.88% to $21.0 million in 2021, then plummeted by 46.25% to $11.3 million in 2022, then tumbled by 320.99% to -$24.9 million in 2023, then skyrocketed by 141.16% to $10.3 million in 2024.